Caribou Biosciences Inc (CRBU)
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on CRISPR-based genome editing. Its platform uses hybrid RNA-DNA technology designed to support precise editing for allogeneic cell therapies. The company’s pipeline includes vispacabtagene regedleucel, an anti-CD19 CAR-T candidate being evaluated in a phase 1 study for relapsed or refractory B-cell non-Hodgkin lymphoma, and CB-011, an anti-BCMA CAR-T candidate in a phase 1 trial for relapsed or refractory multiple myeloma. Incorporated in 2011, Caribou Biosciences is headquartered in Berkeley, California. The listed security is common stock on NASDAQ.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CRBU
|
$1.84
|
37.5% Upside
|
Undervalued
|
$11.86
|
784.9% Upside
|
Bargain
|
Fair
|
0.0%
|
November 10, 2026
|
1.4x
|
13.9x
|
143.7 M
|
52.207 M
|
16.1%
|
96.0%
|
-6.0
|
92.6%
|
